CSL – CSL Limited

Latest News & Stock Analysis

CSL Limited is a global biotechnology leader, headquartered in Australia, specializing in the development and manufacturing of innovative biotherapies and influenza vaccines. The company’s business model focuses on addressing serious and rare diseases through its two main businesses: CSL Behring, which provides plasma-derived and recombinant therapies, and Seqirus, one of the world’s largest influenza vaccine providers. CSL is known for its strong commitment to research and development, continually investing in new treatments and technologies to improve patient outcomes. This innovative approach positions CSL as a key player in the global biotechnology market, offering a diverse portfolio of life-saving products. For the latest news on CSL, analysis of CSL, market trends, investment opportunities, and detailed stock information, follow our updates.

Carlisle Companies: Outperforming the S&P 500. Is It Still a Buy?
CSL

Carlisle Companies: Outperforming the S&P 500. Is It Still a Buy?

by | 08/12/2024 06:00 AM | CSL

📈 Carlisle has outperformed the S&P 500 over the last 10 years.

🧱 70% of revenue comes from construction materials, 30% from weatherproofing technologies.

💰 The company has increased dividends for 48 consecutive years, with a 5-year annual growth rate of 15.5%.

🎯 Aims for a minimum 5% annual organic growth, with 25% of sales from new products by 2030.

Read more!